Capitalizing on Trends in Negotiation, Contracts, and Risk and Reward.
Washington, DC (PRWEB) July 14, 2009
ClearTrial (http://www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kelly Larrabee, Director, Clinical Services, will lead a panel of life sciences executives on the topic of "Capitalizing on Trends in Negotiation, Contracts, and Risk and Reward." The panel discussion, taking place this week at the ExL Effective Business Development for Clinical Trial Service Providers conference in the nation's capital, will give attendees the opportunity to gain practical guidelines for successful trial sponsor/service provider agreements, including the latest trends in bundling services and collaborative technology partnerships.
In addition, attendees will discover:
- How contracting approaches and processes -- such as RFP review, contract structure, metrics and oversight -- have changed due to industry conditions.
- How service providers are successfully utilizing methodologies from other industries for direct cost savings, including lean six sigma, activity-based costing, and earned value management.
- The effectiveness of outcomes-based pricing: risk-based services versus fixed price.
For more information on the conference, visit http://www.exlpharma.com/eventAgenda.php?id=174.
Larrabee brings more than 17 years of clinical operations and clinical project management experience, with both trial sponsors and service providers, to the ExL conference. Prior to joining ClearTrial, she was Associate Director, Clinical Operations for Quintiles, where she oversaw the management of Clinical Research Associates for the Functional Service Provider group for a global sponsor company and led process improvement initiatives related to managing the closure of non-enrolling sites. Before Quintiles, Larrabee was Manager and Regional Study Lead for Pfizer, where she directed project site protocol deliverables for pilot, phase I and phase II oncology studies, and managed the Pfizer Investigator Training Program for the Western Region. Previously, she was Manager, Research Compliance for MD Anderson Cancer Center.
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.